

Title (en)  
OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF

Title (de)  
REKOMBINANTE ONKOLYTISCHE VIREN UND VERWENDUNGEN DAVON

Title (fr)  
VIRUS ONCOLYTIQUES OPTIMISÉS ET UTILISATIONS DE CES DERNIERS

Publication  
**EP 4019029 A1 20220629 (EN)**

Application  
**EP 22151209 A 20170927**

Priority

- US 201662400310 P 20160927
- US 201662426724 P 20161128
- EP 17794108 A 20170927
- US 2017053659 W 20170927

Abstract (en)  
Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors.

IPC 8 full level  
**A61K 35/76** (2015.01); **A61P 35/00** (2006.01)

CPC (source: CN EP US)  
**A61K 35/76** (2013.01 - CN EP US); **A61K 35/768** (2013.01 - CN US); **A61P 35/00** (2018.01 - CN EP); **A61P 43/00** (2018.01 - EP); **C12N 7/00** (2013.01 - CN US); **C12N 15/01** (2013.01 - CN EP US); **G01N 33/5011** (2013.01 - CN US); **C12N 2770/32321** (2013.01 - CN US); **C12N 2770/32332** (2013.01 - CN US); **C12N 2770/32351** (2013.01 - CN US); **G01N 2333/085** (2013.01 - CN US); **Y02A 50/30** (2018.01 - EP US)

Citation (search report)

- [X] WO 2014081346 A2 20140530 - MATVEEVA OLGA VYACHESLAVOVNA [RU], et al
- [X] LE BOEUF F ET AL: "Synergistic interaction between oncolytic viruses augments tumor killing", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 18, no. 5, 1 May 2010 (2010-05-01), pages 888 - 895, XP002736976, ISSN: 1525-0024, [retrieved on 20100316], DOI: 10.1038/MT.2010.44
- [X] J. R. TYSOME ET AL: "A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity", CLINICAL CANCER RESEARCH, vol. 18, no. 24, 22 October 2012 (2012-10-22), US, pages 6679 - 6689, XP055431423, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-0979
- [X] ESTANISLAO NISTAL-VILLAN ET AL: "Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model", MOLECULAR CANCER, vol. 14, no. 1, 1 December 2015 (2015-12-01), XP055431208, DOI: 10.1186/s12943-015-0479-x
- [A] HOWARD L. KAUFMAN ET AL: "Oncolytic viruses: a new class of immunotherapy drugs", NATURE REVIEWS. DRUG DISCOVERY, vol. 14, no. 9, 1 September 2015 (2015-09-01), GB, pages 642 - 662, XP055266462, ISSN: 1474-1776, DOI: 10.1038/nrd4663
- [X] MUHANNAD ALKASSAR ET AL: "The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo", JOURNAL OF NEURO-ONCOLOGY, KLUWER ACADEMIC PUBLISHERS, BO, vol. 104, no. 3, 24 May 2011 (2011-05-24), pages 715 - 727, XP019948337, ISSN: 1573-7373, DOI: 10.1007/S11060-011-0606-5
- [X] SUSKIND R G ET AL: "Viral agents oncolytic for human tumors in heterologous host; oncolytic effect of Coxsackie B viruses", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, SAGE PUBLICATIONS LTD, GB, vol. 94, no. 2, 1 February 1957 (1957-02-01), pages 309 - 318, XP009131831, ISSN: 0037-9727
- [X] DEMINA ET AL: "NON-PATHOGENIC ENTEROVIRUSES POSSESSING POTENTIAL ONCOLYTIC PROPERTIES", 1 January 2014 (2014-01-01), pages 62 - 64, XP055706015, Retrieved from the Internet <URL:https://openbio.ru/openbio\_tezis\_2014.pdf> [retrieved on 20200617]
- [X] STINA ISRAELSSON ET AL: "Cytolytic replication of echoviruses in colon cancer cell lines", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 14 October 2011 (2011-10-14), pages 473, XP021114031, ISSN: 1743-422X, DOI: 10.1186/1743-422X-8-473
- [X] ALLOUSSI S.: "All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma", ONCOLOGY REPORTS, vol. 26, 1 January 2011 (2011-01-01), pages 645 - 649, XP055917367, ISSN: 1021-335X, DOI: 10.3892/or.2011.1331
- [X] KIM MANBOK: "Naturally occurring reoviruses for human cancer therapy", BMB REPORTS, vol. 48, no. 8, 31 August 2015 (2015-08-31), KR, pages 454 - 460, XP055917368, ISSN: 1976-6696, DOI: 10.5483/BMBRep.2015.48.8.076

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**US 11253558 B2 20220222; US 2018085411 A1 20180329;** AU 2017335673 A1 20190411; BR 112019005700 A2 20210727; CA 3037573 A1 20180405; CN 109982708 A 20190705; CN 109982708 B 20230523; CN 117085047 A 20231121; EP 3518947 A1 20190807; EP 3518947 B1 20230705; EP 3518947 C0 20230705; EP 4019029 A1 20220629; EP 4023233 A2 20220706; EP 4023233 A3 20220921; JP 2019533015 A 20191114; JP 2022164823 A 20221027; JP 2024069529 A 20240521; JP 7138946 B2 20220920; JP 7462345 B2 20240405; MX 2019003546 A 20190919; MX 2023011105 A 20231002; MX 2024004156 A 20240423; US 2022088097 A1 20220324; US 2022088098 A1 20220324; WO 2018064134 A1 20180405

DOCDB simple family (application)  
**US 201715716974 A 20170927;** AU 2017335673 A 20170927; BR 112019005700 A 20170927; CA 3037573 A 20170927; CN 201780072002 A 20170927; CN 202310850191 A 20170927; EP 17794108 A 20170927; EP 22151209 A 20170927; EP 22151215 A 20170927; JP 2019538097 A 20170927; JP 2022137786 A 20220831; JP 2024042134 A 20240318; MX 2019003546 A 20170927; MX 2023011105 A 20190327; MX 2024004156 A 20190327; US 2017053659 W 20170927; US 202117543206 A 20211206; US 202117543333 A 20211206